Can we afford not to prevent MS-related disability?

Kobelt G Berg J Lindgren P . Costs and quality of life in multiple sclerosis in Europe: Method of assessment and analysis. Eur J Health Econ 2006; 7(Suppl. 2): S5–13.

Kobelt G Thompson A Berg J . New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 2017; 23(8): 1123–1136.

Giovannoni G Butzkueven H Dhib-Jalbut S . Brain health: Time matters in multiple sclerosis. Mult Scler Relat Disord 2016; 9(Suppl. 1): S5–S48.

Ascherio A Munger KL Lünemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012; 8(11): 602–612.

Hobart J Kalkers N Barkhof F . Outcome measures for multiple sclerosis clinical trials: Relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler 2004; 10(1): 41–46.

Orme M Kerrigan J Tyas D . The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007; 10(1): 54–60.

Strober L Chiaravalloti N Moore N . Unemployment in multiple sclerosis (MS): Utility of the MS Functional Composite and cognitive testing. Mult Scler 2014; 20(1): 112–115.

Giovannoni G Butzkueven H Dhib-Jalbut S . Brain health: Time matters in multiple sclerosis, http://www.msbrainhealth.org/perch/resources/time-matters-in-ms-report-may16.pdf

Bozkaya D Livingston TP Migliaccio-Walle K . The cost-effectiveness of disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis. Value Health 2015; 18(3): A283.

Tice JA Chapman R Kumar V . Disease-modifying therapies for relapsing remitting and primary-progressive multiple sclerosis: Effectiveness and value. Institute for Clinical and Economic Review, 2017, p. 217, https://icer-review.org/wp-content/uploads/2016/08/ICER_Draft_MS_Report_112216.pdf

Marziniak M Ghorab K Kozubski W . Variations in multiple sclerosis practice within Europe – Is it time for a new treatment guideline? Mult Scler Relat Disord 2016; 8: 35–44.

Giovannoni G. Why do you have to be lucky to get the MS treatment you deserve? Mult Scler Relat Disord 2016; 8: A3–A4.